CJC-1295

GHRH analog discussed for GH axis support.

GHRH receptor signaling; GH axis modulation.

CJC-1295 No DAC, also known as Modified GRF 1-29, is a short-acting analog of the body's own growth-hormone-releasing hormone (GHRH). It stimulates the pituitary gland to release a burst of growth hormone, which then clears from the body in approximately 30 minutes. This mechanism allows for a rapid increase in growth hormone levels, which can be beneficial for various physiological processes.

The peptide is typically administered in a fasted state, as food intake, particularly carbohydrates, can dampen the growth hormone pulse due to insulin's inhibitory effects on growth hormone signaling. Most protocols recommend injecting at least two hours after eating and 30 minutes before the next meal. Pre-bed dosing is particularly effective as it aligns with the body's natural growth hormone pulse during deep sleep.

CJC-1295 No DAC is often paired with Ipamorelin in research protocols, as these two compounds activate the pituitary gland through different mechanisms, potentially enhancing the overall effect on growth hormone release. The dosing patterns for CJC-1295 No DAC are generally structured to start low and increase gradually, with a common titration framework that includes phases of initiation, early escalation, therapeutic range, and advanced range. This careful titration is important because the short half-life of the peptide means that each dose is largely independent, allowing for flexibility in dosing schedules.

Despite the promising mechanism of action, it is important to note that CJC-1295 No DAC is not FDA-approved and is used strictly in research contexts. The dosing patterns and protocols are extrapolated from studies on the parent CJC-1295 sequence and GHRH pharmacology, as no large clinical trials have specifically tested the No DAC variant at a protocol scale. [Source: Peptide Dosing Protocols]